Physician profile
Daniel O Young
NPI 1184742520
$1,487.05
in general payments reported to CMS, 2019-2025
20 companies · $291 in 2025
The $291 reported for 2025 was more than what 83% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $84.45 · 2021: $17.02 · 2022: $16.31 · 2023: $209 · 2024: $624 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.37 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.92 | 2019-2024 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $220.76 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.07 | 2023 | Jardiance |
| Mallinckrodt Enterprises LLC | $119.64 | 2019 | |
| Fresenius USA Marketing, INC. | $102.95 | 2023-2024 | Velphoro, Korsuva, Optiflux |
| Novartis Pharmaceuticals Corporation | $68.53 | 2024-2025 | |
| Novo Nordisk INC | $67.83 | 2024-2025 | Ozempic |
| Amgen INC. | $65.93 | 2024-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $60.94 | 2019-2024 | Veltassa |
| Travere Therapeutics, INC. | $56.89 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.51 | 2021-2024 | |
| Glaxosmithkline, LLC. | $44.76 | 2025 | Benlysta |
| Calliditas Therapeutics US INC. | $41.89 | 2025 | Tarpeyo |
| Horizon Therapeutics Plc | $27.02 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $22.62 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.21 | 2023 | Jynarque |
| Vantive US Healthcare LLC | $20.94 | 2025 | Renal - Pd |
| Baxter Healthcare | $20.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.23 | 2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $17.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.